Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 12, 2018
Neovasc Announces Amendments to Outstanding Convertible Notes, including 1-Year Extension of Note Maturity Date
VANCOUVER, Sept. 12, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies ...
September 12, 2018
Athenex and its Collaborative Partner, Hanmi Pharmaceutical, Announce Strategic Realignment of their Joint Projects
BUFFALO, N.Y., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
September 12, 2018
PolarityTE, Inc. Reports Financial Results and Corporate Update for Quarter End July 31, 2018
SALT LAKE CITY, Sept. 12, 2018 /PRNewswire/ -- PolarityTE, Inc. (COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients ...
September 12, 2018
Fortress Biotech Announces Publication of Preclinical Data on AAV-ATP7A Gene Therapy Combined with CUTX-101 (Copper Histidinate) for Menkes Disease in Molecular Therapy: Methods & Clinical Development
NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and ...
September 12, 2018
BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn® Cellular Therapy Platform
NEW YORK and PETACH TIKVAH, Israel, Sept. 12, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics ...
September 11, 2018
OSE Immunotherapeutics Announces Issuance of a European Patent Protecting FR104, CD28-Antagonist Immunotherapy
NANTES, France, Sept. 11, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), has strengthened its intellectual property rights for the developmental product ...
September 11, 2018
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation ...
September 11, 2018
Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 11, 2018/PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that new ...
September 11, 2018
Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing ...
September 10, 2018
Innate Pharma announces data presentations at upcoming scientific meetings
Marseille, France, September 10, 2018, Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced that updated data from ongoing clinical trials evaluating ...
September 10, 2018
Sensorion to Partner with Vestibular Disorders Association (VeDA) in Sponsorship of Balance Awareness Week 2018 for Vestibular Disorders
MONTPELLIER, France, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Sensorion(FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that ...
September 10, 2018
BioDelivery Sciences to Present at the 2018 Janney Montgomery Scott Healthcare Conference
RALEIGH, N.C., Sept. 10, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a leading commercial stage specialty pharmaceutical company dedicated to patients living with ...
September 10, 2018
Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
SANTA MONICA, Calif., and HEMEL HEMPSTEAD, United Kingdom, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing pharmacological ...
September 10, 2018
TRACON Pharmaceuticals Announces Publication of Phase 1b Results for TRC105 in Combination with Inlyta® in Patients with Advanced or Metastatic RCC
SAN DIEGO, Sept. 10, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
September 7, 2018
OSE Immunotherapeutics Reports First-Half 2018 Results and Provides a Corporate Update
NANTES, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), today reported its consolidated half-year financial results as of June ...
September 7, 2018
Zealand sells royalty streams and milestones for USD 205 million to Royalty Pharma
Copenhagen, September 6, 2018 - Zealand Pharma A/S ("Zealand") (ZEAL.CO), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today ...
September 7, 2018
ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation ...
September 7, 2018
Zealand Pharma to attend J.P. Morgan Cazenove and Morgan Stanley Global Healthcare Conferences
Copenhagen, September 7, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will attend the J.P. Morgan Cazenove Pan-European ...
September 7, 2018
Novus Therapeutics to Postpone Offering of Common Stock
IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), ...
September 6, 2018
Kiadis Pharma announces two senior management appointments
Amsterdam, The Netherlands, September 6, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today ...
Page 30 of 128